Top Markets
#1 CoW Protocol CoW Protocol +59.73%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +38.71%
#4 Cysic Cysic +31.67%
#5 Walrus Walrus +25.77%
#6 Humanity Humanity +22.30%
#7 Enso Enso +18.12%
#8 Velvet Velvet +17.00%
#9 Tutorial Tutorial +15.35%
#10 The Black Bull The Black Bull +13.56%
Coin of the day
CoW Protocol CoW Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Classifica tra le azioni #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Prezzo delle azioni
$0.6
Ultima sincronizzazione: 2024-08-14
Capitalizzazione di mercato
$2.09M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
SG
Scambia ASLAN Pharmaceuticals Limited (ASLN)

Categoria

Healthcare
Ricavi di ASLAN Pharmaceuticals Limited (ASLN)
Ricavi nel Mar 2024 TTM: $12.00M
Secondo gli ultimi rapporti finanziari di ASLAN Pharmaceuticals Limited, i ricavi attuali dell'azienda (TTM) sono pari a $12.00M. Nel 2022, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2021, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per ASLAN Pharmaceuticals Limited da 2014 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $12.00M 0.00%
2023 $12.00M 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $3.00M 0.00%
2018 0.00 0.00%
2017 0.00 -100.00%
2016 $11.49M 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 105,102.50%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 50,077.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 84,156.56%
BE